Elizabeth Y Swift

US Patent:

20190202823, Jul 4, 2019

Filed:

Mar 6, 2019

Appl. No.:

16/293973

Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Brian S. Brown - Evanston IL, US
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Elsa De Lemos - Paris, FR
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Nuria Merayo Merayo - Paris, FR
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V. Patel - Round Lake IL, US
Matthieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Steven Emiel Van der Plas - Steenhuffel, BE
Xueqing Wang - Sunnyvale CA, US
Ann de Blieck - Mechelen, BE

International Classification:

C07D 471/04
A61K 45/06
A61K 31/5377
A61K 31/4545
C07D 519/00
A61K 31/437
A61K 31/506

Abstract:

The present invention provides for compounds of formula (I)wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

US Patent:

20180105522, Apr 19, 2018

Filed:

Dec 15, 2017

Appl. No.:

15/843917

Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Brian S. Brown - Evanston IL, US
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Elsa De Lemos - Paris, FR
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Nuria Merayo Merayo - Paris, FR
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V. Patel - Round Lake IL, US
Matthieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Steven Emiel Van der Plas - Steenhuffel, BE
Xueqing Wang - Northbrook IL, US
Ann de Blieck - Mechelen, BE

International Classification:

C07D 471/04
A61K 45/06
A61K 31/437
C07D 519/00
A61K 31/506
A61K 31/5377
A61K 31/4545

Abstract:

The present invention provides for compounds of formula (I)wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

US Patent:

20170100386, Apr 13, 2017

Filed:

Oct 7, 2016

Appl. No.:

15/288400

Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Brian S. Brown - Evanston IL, US
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Katja E. Conrath - Mechelen, BE
Douglas Cyr - Chapel Hill NC, US
Elsa De Lemos - Paris, FR
Gert Jules Hector De Wilde - Mechelen, BE
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Nuria Merayo Merayo - Paris, FR
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V. Patel - Round Lake IL, US
Mathieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Chris Tse - Libertyville IL, US
Steven Emiel Van der Plas - Steenhuffel, BE
Xueqing Wang - Northbrook IL, US

International Classification:

A61K 31/4545
G01N 33/50
A61K 45/06

Abstract:

A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.

US Patent:

20170101405, Apr 13, 2017

Filed:

Oct 7, 2016

Appl. No.:

15/287911

Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Brian S. Brown - Evanston IL, US
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Elsa De Lemos - Paris, FR
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Nuria Merayo Merayo - Paris, FR
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V. Patel - Round Lake IL, US
Matthieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Steven Em iel Van der Plas - Steenhuffel, BE
Xueqing Wang - Northbrook IL, US
Ann de Blieck - Mechelen, BE

International Classification:

C07D 471/04
A61K 31/4545
A61K 31/437
A61K 31/506
A61K 45/06
A61K 31/5377

Abstract:

The present invention provides for compounds of formula (I)wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

US Patent:

20170101406, Apr 13, 2017

Filed:

Oct 7, 2016

Appl. No.:

15/287922

Inventors:

- Luxembourg, LU
- Mechelen, BE
Xavier Marie Bock - Romainville, FR
Pieter Isabelle Roger Claes - Gentbrugge, BE
Marlon D. Cowart - Round Lake Beach IL, US
Elsa De Lemos - Paris, FR
Nicolas Desroy - Massy, FR
Béranger Duthion - Paris, FR
Gregory A. Gfesser - Lindenhurst IL, US
Romain Luc Marie Gosmini - Savigny-sur-Orge, FR
Christopher Gaëtan Housseman - Montreuil, FR
Koen Karel Jansen - Turnhout, BE
Jianguo Ji - Libertyville IL, US
Philip R. Kym - Libertyville IL, US
Jean-Michel Lefrancois - Le Raincy, FR
Oscar Mammoliti - Mechelen, BE
Christel Jeanne Marie Menet - Brussels, BE
Gregory John Robert Newsome - Neuilly Plaisance, FR
Adeline Marie Elise Palisse - Brussels, BE
Sachin V Patel - Round Lake IL, US
Mathieu Rafaël Pizzonero - Voisins le Bretonneux, FR
Anurupa Shrestha - Vernon Hills IL, US
Elizabeth C. Swift - Highland Park IL, US
Steven Emiel Van der Plas - Steenhuffel, BE
Xueqing Wang - Northbrook IL, US

International Classification:

C07D 471/04
A61K 31/5377
C07D 519/00
A61K 31/496
A61K 31/541
A61K 31/506
A61K 45/06
A61K 31/437

Abstract:

The present invention provides for compounds of formula (I)wherein R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).